Kornimate/medical-research-clean huggingface dataset:
using wearable device to improve quality of palliative care

Conditions: Terminal Cancer; End Stage Cancer

Summary: this study is going to use wearable devices and smartphones to collect physical data from terminal patients and build a survival predicting model for terminal patients with machine learning. investigators hypothesize that continuous physical data monitoring could offer a hint to better predictability in end-of-life care.

the study aim to examine the feasibility of utilizing wearable devices and smartphones in palliative patients in taiwan. in addition, investigators try to identify the relationship between mobile health data and disease progression and establish a predicting model to the emergent medical need and death of patients, via machine learning. this is a single-arm observational study using wearable devices and smartphones in terminal cancer patients. investigators planned to enroll 75 patients who receive palliative care. after obtaining consent from the patients or their legally authorized surrogate decision-makers, a baseline assessment will be conducted, with a guide to use wearable devices and phone apps. investigators will keep regular follow-up for 52 weeks or until the participants' death. assessment will be conducted every week, face-to-face or by telephone contact. a routine assessment includes symptoms and functionality in the past week, and vital signs and facial photograph will be recorded if possible. physical data measured from wearable devices would be recorded continuously. the emergent medical needs of patient, including emergency department visit, unplanned admission and death of participants will be recorded if happen. the primary outcome is the predictive performance (sensitivity and specificity) of the machine-learning model using wearable device data and symptoms assessment. the secondary outcomes are symptoms, including pain, dyspnea, diarrhea, constipation, nausea, vomiting, insomnia, depression, anxiety and fatigue. users' opinion and comment to using experience will also be recorded.

Eligibility criteria:
inclusion criteria * age: 20 years old or older * clinical diagnosis: cancer in terminal stage. exclusion criteria - cannot cooperate with use of wearable devices or smartphones.

Keywords: palliative cancer survival prediction artificial intelligence wearable devices
effect of single doses of 10 mg nrl001 applied as a suppository to the anal canal or rectum

Conditions: Fecal Incontinence

Summary: study to assess the effects of 10mg nrl001 on mean anal resting pressure (marp) when administered as a slow release suppository applied to the anal canal or rectum. in addition, the pharmacokinetics of nrl001 in plasma, adverse events, and any changes in heart rate or blood pressure were to be assessed.


Eligibility criteria:
inclusion criteria: * no previous history of ano-rectal conditions/ diseases * no history of cardiovascular disease * 18 to 75 years of age * males and females (pre-menopausal females of child-bearing potential must be using adequate contraceptive methods and have a negative pregnancy test before the start of the study) exclusion criteria: * use of medication in the last 30 days with a vasodilatory activity * use of monoamine oxidase inhibitors (maoi) presently or within the last two weeks before study participation * use of any medication in the last 30 days applied to the anus and/or via the rectum (exception: participation in nrl001-01/2006 (supp) for previous dosing into the anal canal) * application of any unlicensed medication within the previous 3 months (exception: participation in nrl001-01/2006 (supp)) * regular intake of more than 21 units of alcohol per week * history or any evidence of cardiovascular disease including ischaemic heart disease and hypertension (defined on examination: systolic blood pressure greater than 160mmhg or diastolic blood pressure greater than 90mmhg; based on at least two separate readings), peripheral vascular disease or raynaud's syndrome * presence of diabetes mellitus * history or symptoms of thyroid diseases, including hypo- or hyperthyroidism * pregnant females * breast feeding mothers * presence of concomitant gastrointestinal diseases or disorders, such as significant abdominal symptoms and haemorrhoids but also any significant organ (e.g. renal, hepatic or cardiac) dysfunction * volunteers whom the investigator feels would not be compliant with the requirements of the trial
factors for the onset and course of axial spondylitis

Conditions: Axial Spondyloarthritis

Summary: in a research project, investigators want to study the course of the disease of axial spondylitis: the causes of disease onset, prognosis, and treatment effects. the goal is to improve treatment and in the long run also prevention of the disease. the project has a focus on the body\&#39;s own substance prostaglandin, and its proinflammatory role in spondylitis, but also other substances may be analyzed in blood and urine samples. the purpose of the research project is include newly diagnosed treatment-naive patients with axial spondyloarthritis, to follow them after 1 and 2 years after treatment start, to collect clinical data, questionnaires, blood and urinsamples to find blood or urine markers that can be used for precision therapy of axial spondylitis.

the eispa study is an epidemiological and translational study in axial spondylitis patients who are included in the swedish rheumatology quality register (srq). eispa aims to include consecutive newly diagnosed axial spondylitis patients. despite the fact that the disease is relatively common, it takes on average 10 years after start of symptoms for patients be diagnosed with axial spondylitis. axial spondylitis diagnosis is based on clinical findings rather than diagnostic tests, which reflects lack of knowledge about what causes the disease. at present, our possibilities to predict the course of the disease (and thereby individualize the care of the patient) are limited. current treatment decreases inflammation rather than treating the cause of the disease. the first treatment step of axial spondylitis is with non-steroidal anti-inflammatory drugs or cox inhibitors, which usually have insufficient effect against inflammatory pain and stiffness. in addition, these drugs are associated with side effects, such as gastrointestinal and cardiovascular side effects. axial spondylitis is a multifactorial disease where the arachidonic acid cascade, an increased prostaglandin production and release may play a major role. with this there is a clear potential to develop new specific drugs to slow down the prostaglandin cascade in patients with axial spondylitis.

Eligibility criteria:
inclusion criteria: * newly diagnosed patients with axial spondyloarthritis * treatment-naive * 18 years of age or older * swedish-speaking * able to give informed consent exclusion criteria: * dmard treatment, * ongoing infection * ongoing malignancy

Keywords: observational axial spondyloarthritis prostaglandins predictive factors
a study of ro5313534 as add-on to donepezil treatment in patients with mild to moderate alzheimer's disease

Conditions: Alzheimer's Disease

Summary: this 4 arm study will assess the efficacy and safety of ro5313534 (mem3454) versus placebo added to donepezil, in patients with mild to moderate alzheimer's disease. following a screening period, patients will be randomized to one of 4 treatments (placebo, or ro5313534 1mg, 5mg or 15mg po daily) with background therapy of donepezil (5mg or 10mg).the anticipated time on study treatment is 6 months, and the target sample size is 100-500 individuals.


Eligibility criteria:
inclusion criteria: * adult patients, \>/=50 years of age; * probable alzheimer's disease; * mmse score at screening of 13-22; * under stable donepezil treatment given at a fixed dose of 5 or 10mg daily for \>=4 months prior to baseline; * not requiring nursing home care, but looked after by a caregiver/carer. exclusion criteria: * dementia due to condition other than alzheimer's disease; * other significant neurological disorder; * untreated/non-stabilized major depressive disorder; * bipolar disorder, schizophrenia, or any other serious psychiatric condition.
erector spinae block versus thoracic paravertebral block for postoperative pain control after open nephrectomy

Conditions: Pain, Postoperative

Summary: the study aims to compare the analgesic efficacy of erector spinae plane block versus thoracic paravertebral block after open nephrectomy surgery.

open nephrectomy is associated with substantial postoperative pain, pain relief in patients undergoing this procedure is usually provided either by thoracic epidural analgesia (ea) or systemic analgesics. ea is a very useful option for the management of postoperative pain in patients undergoing abdominal surgeries, but the risks and contraindications linked to ea like hypotension ,headache ,nerve damage or infection may limit its use. systemic analgesics in the form of opioid analgesics may give rise to side effects like nausea ,vomiting ,constipation, allergy or drowsiness and often provide insufficient analgesia. hence, other methods of postoperative pain management are desired. sensory level target according to the incision site flank(t9-t11) , thoraco-abdominal (t7-t12 ) and trans-abdominal (t6-t10). ultrasound (us) guided erector spinae plane (esp) block is one of the interfascial plane blocks that target the dorsal and ventral rami of the spinal nerves. although there is no sufficient evidence for the spread of local anesthetic to the ventral rami, recent anecdotal reports demonstrated effective postoperative analgesia after thoracic and lumbar surgeries affecting both the ventral and dorsal rami .according to a previous study, erector spinae plane block has allowed a reduction in opioid consumption and excellent pain control in partial nephrectomy. paravertebral block (pvb) is a technique where a local anesthetic is deposited into a space found on both sides of the spine, called the paravertebral space. it is a block with a dermatomal distribution of pain relief depending on the level of the spine at which the block is sited and the quantity and type of deposited local anesthetic. pvb is effective for pain relief in the thoracic, abdominal and limb regions .

Eligibility criteria:
inclusion criteria: * adult patients (30-60 years) . * patients with asa i , ii score exclusion criteria: * patient's refusal * coagulopathy to be cancelled if ( inr\>1.4 , platelets count \<100x109 ) * infection at the injection site. * allergy to local anesthetics. * patients receiving opioids for chronic analgesic therapy

Keywords: open nephrectomy
safety, pk/pd (pharmacokinetics/pharmacodynamics) and efficacy of acp-001 weekly versus daily hgh in children with growth hormone deficiency (ghd)

Conditions: Growth Hormone Deficiency (GHD)

Summary: a six month study of acp-001, a long-acting growth hormone product, versus standard human growth hormone therapy. acp-001 will be given once-a-week, standard human growth hormone (hgh) will be given on a daily basis. the primary aim is to demonstrate safety, pharmacokinetics and pharmacodynamics over a period of six months. a secondary objective is the comparison of height velocity (hv) of the acp-001 treated groups to the daily hgh treatment group.


Eligibility criteria:
inclusion criteria: * prepubertal children, tanner stage 1 * diagnosis of ghd, confirmed by two stimulation tests * bone age not greater than chronological age * impaired height and height velocity * bmi within +/- 2 sd (standard deviations) * baseline igf-1 (insulin-like growth factor) * normal fundoscopy * stable hormonal replacement therapy (other than hgh) * written informed consent exclusion criteria: * prior exposure to rhgh or igf-i * past or present intracranial tumor; history or presence of malignant disease * small for gestational age (sga) * malnutrition * psychosocial dwarfism * coeliac disease * anti-hgh antibodies * diabetes mellitus * chromosomal abnormalities (e.g. turner syndrome, shox) * closed epiphyses * known or suspected hiv infection

Keywords: human growth hormone rhgh hgh ghd
effect of propolis on patients infected with h. pylori

Conditions: Helicobacter Pylori Infection

Summary: this research aims to contribute to the literature by researching the effect of propolis as an add-on treatment and nutritional education on patients with h pylori and the alleviation of gastrointestinal symptoms.in order to achieve this, we offered propolis and educational nutrion programme to our 96 patients and check on their symptoms on a regular basis to note any improvement by measuring the alleviation using gsrs.

the informed voluntary consent was taken from the patients who agreed to attend the research and the patients, group 1 propolis with lactic acid extract on top of the treatment given by doctor group 2 lactic acid extract on top of the treatment by the doctor group 3 the treatment given by the doctor and placebo treatment ,will be distributed by the method of randomized double blind trial.the patients will be provided with 500 mg (≌60 drops/day) of propolis or propolis with lactic acid extract in the morning,afternoon and evening for 14 days.the face-to-face survey data collection method will be utilized and the researcher inform the patients about the diet and nutrition education against pylori and propolis.the presentation for the patient education and propolis is given in the appendix. the survey form consists of 4 parts; descriptive general information,eating habits,gastrointestinal symptoms rating scale (gsrs) and the frequency of the consumption of particular food. in order to rate the gastrointestinal symptoms of the patients the gsrs scale which was validated and deemed reliable in turkish will be used the foods that increase the frequency of gastrointestinal symptoms such as spicy foods,chocolate,chips,carbonated drinks,citrus fruits are also questioned in terms of frequency of consumption. in order to investigate the patients adherence to the study, reminders will be taking place by giving them a call two times a week. at the end of the intervention period,gsrs scale will be reused to assess the patients.

Eligibility criteria:
inclusion criteria: * the detection of h pylori infection by a specialized physician. exclusion criteria:bees and bees products allergies and the patients who use drugs that has bleomycin as an active compound will be excluded as it was found in the rats that these types of antitumor drugs can interact with propolis

Keywords: h.pylori,propolis,nutritional education,pud
statistical analysis of pediatric task force data base

Conditions: Cardiovascular Diseases; Heart Diseases; Hypertension

Summary: to define pediatric sex-specific blood pressure percentiles that were a function of both age and height. also, to define the precise age at which blood pressure distributions for different racial groups diverged.

background: hypertension is a well-recognized risk factor for cardiovascular disease in adults. furthermore, many studies have shown that there is tracking among longitudinal pediatric blood pressure determinations. an important unresolved goal in pediatric hypertension research is to define at what level of pediatric blood pressure is a child at increased risk for adult hypertension. when the grant was awarded in february 1991, there had been two nhlbi task forces in blood pressure control in children which had published reports in 1977 and 1987. one of the goals of each task force was to define appropriate percentiles for blood pressure in children. in the second task force report, results from nine large epidemiologic studies were combined into a data base with more than 70,000 readings from which blood pressure percentiles were derived as a function of age and sex. however, many research workers stated that height is more strongly related to blood pressure than age and have urged that normative data for pediatric blood pressure be demarcated by height rather than age. design narrative: blood pressure percentiles were constructed that were a function of age, sex, race, and height, thus providing a more comprehensive profile of pediatric blood pressure distributions than any previously published work. the study completion date listed in this record was obtained from the "end date" entered in the protocol registration and results system (prs) record.

Eligibility criteria:
no eligibility criteria
audio health engagement analysis in diabetes: the ahead study

Conditions: Type 1 Diabetes

Summary: despite multidisciplinary care and advancements in therapeutics and technology, health outcomes remain suboptimal in pediatric diabetes centers world-wide. a major contributor to poor outcomes is suboptimal diabetes management in pediatric patients and their families. the premise of this research project is that patients and families do not have adequate resources to meet the level of diabetes management that translates to better outcomes. therefore, we will give them a valuable tool to improve their overall management. the tool is carecoach. research shows that enhancing communication and partnership among patients, parents, and providers is especially critical for optimal outcomes in pediatric diabetes. communication gaps and conflict can complicate the already complex provider-patient interactions and daily management. we have therefore designed, refined, and made available to consumers a new mobile-based intervention, carecoach, to improve communication; build trust among providers, patients and parents; and increase overall satisfaction with the quality of diabetes care. this web/mobile application is designed to help patients unobtrusively audio record their clinical encounters, track their medical consults and treatment plans, review information from past visits, create visit discussion guides, and track adherence to medication and dosing schedules. in addition, because mobile-based applications are inexpensive to administer, portable, and available at all times of day, carecoach holds great promise for communication coaching and contributing to improved diabetes management. we hypothesize that carecoach will improve patient-parent-provider communications, build patient-parent-provider trust, and increase overall satisfaction with clinical interactions in a sample of children with type 1 diabetes and their parents. these improvements will lead to significant gains in diabetes management, setting the stage for optimal health outcomes. to test the effectiveness of carecoach, we will conduct a randomized controlled trial comparing the carecoach intervention to standard care in a sample of 60 children with type 1 diabetes and their parents.


Eligibility criteria:
inclusion criteria: * parent of a child with diagnosis of type 1 diabetes for at least one year * parent of a child with type 1 diabetes between the ages of 7-12 * provide informed consent in english * have access to the internet from home exclusion criteria: * no access to the internet * shorter duration of type 1 diabetes than one year

Keywords: type 1 diabetes parents mobile application diabetes management
international consortium investigating early vitrectomy in diabetic macular edema patients

Conditions: Diabetes With Diabetic Retinopathy With Macular Edema

Summary: the purpose of this research is to evaluate the effectiveness of vitrectomy for the treatment of diabetic macular edema. diabetes is known to cause retinal blood vessels to leak, leading to swelling of the central retina (macula), and decreased vision. removing the vitreous gel with vitrectomy surgery is known to decrease the swelling caused by diabetes. diabetic retinopathy is often treated with laser or injections of medicine in to the eye.


Eligibility criteria:
inclusion criteria: * men and women, \> 18 years of age with type 1 or 2 diabetes mellitus diagnosed and treated by an endocrinologist, internist or family medicine physician * background diabetic retinopathy * dme with central subfield thickness (cst) \> 325 µm by spectral domain optical coherence tomography (sd-oct) * hba1c level of \< 10.0 mg/dl * previous cataract surgery with implantation of a stable posterior chamber intraocular lens or a phakic eye with 1+ (out of 4+ scale) or less lens opacification * predominantly intact (80%) external limiting membrane (elm) and photoreceptor inner/outer segment (is/os) lines within 500 µm of the fovea on horizontal and vertical sd-oct scans * best corrected snellen visual acuity from 20/40 to 20/280 inclusive. exclusion criteria: * intraocular anti-vascular endothelial growth factor (vegf) injection within the previous 3 months * systemic anti-vegf or receptor tyrosine kinase inhibitor therapy within the previous 3 months * intraocular corticosteroid injection within the previous 6 months * peri-ocular corticosteroid injection within the previous 3 months * vitreomacular traction on sd-oct scan (epiretinal membrane is allowed) * previous anterior or pars plana vitrectomy * glaucoma (iop of \> 21 mmhg or regular use of more than 2 iop lowering drugs) * previous trabeculectomy * likelihood of needing intraocular surgery within 6 months * hard exudates involving the fovea * proliferative diabetic retinopathy with any evidence of retinal traction * cataract of grade 2+ or greater.
estimating lymphocyte counts from dna methylation

Conditions: Colorectal Cancers; Immunotherapy; DNA Methylation

Summary: the goal of this observational study is to assess lymphocyte levels in colorectal cancer patients using dna methylation levels in tissues or blood. the main questions it aims to answer are: can dna methylation features calculate lymphocyte levels? can the calculated lymphocyte levels assess the efficacy and prognosis of immunotherapy?


Eligibility criteria:
inclusion criteria: 1. diagnosed with colorectal cancer by colonoscopy pathology and deemed eligible for immunotherapy after assessment. 2. neoadjuvant immunotherapy regimen includes pd-1 or anti-pd-l1. 3. r0 resection is performed after neoadjuvant immunotherapy. 4. complete immunotherapy efficacy assessment data and follow-up data are available. 5. the tissue bank stores the required whole blood and tissue samples for the experiment. exclusion criteria: 1. concurrent other malignancies. 2. neoadjuvant immunotherapy not conducted according to the standard protocol. 3. severe adverse chemotherapy reactions that lead to the discontinuation of immunotherapy midway. 4. lack of complete neoadjuvant chemotherapy efficacy assessment data or follow-up data. 5. the tissue bank does not store the required whole blood or tissue samples for the experiment. 6. patients with concurrent other immune system diseases.
effects of core strengthening on pelvic tilt, dynamic balance and agility in lower cross syndrome: a quasi-experimental study

Conditions: Lower Cross Syndrome

Summary: this study is a quasi experimental study and the purpose of this study is to determine the effects of core strengthening on pelvic tilt, dynamic balance and agilty in lower cross syndrome.

participants will be recruited into the study using the criteria of lower crossed syndrome which is assessed using te following tests: prone hip extension test trunk flexion strength test tightness in erector spinae modified thomas test

Eligibility criteria:
inclusion criteria: * age 19-35 years * both genders * positive modified thomas test * positive prone hip extension strength test * positive trunk flexion strength test * tight erector spinae * asia pacific bmi normal (18.5-24.9 kg/m2) * local intermittent lumbar pain * moderate pain (nprs 3-7) * painless movement and activity * pain only produced by sustained loading in relevant position, which is then relieved on moving from that pos exclusion criteria: * acute flare of lbp * centralization and peripheralization of pain * signs of stenosis(leg symptoms when walking that are eased upon flexion) * pain due to repetitive movements * paresthesia/numbness * structual deformity(kyphosis, spondylosis, spondylolisthesis,scoliosis and joint contractures) * curve reversal * pregnancy * post surgery * degenerative and inflammatory spine diseases